Credas Labs Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 4.84 M
- Company Age 3 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.90 Cr
- Revenue Growth 36.35%
- Profit Growth 147.16%
- Ebitda 346.12%
- Net Worth 2859.21%
- Total Assets 27.74%
About Credas Labs
Credas Labs Private Limited (CLPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 June 2021 (Three years and eight months 19 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.84 M.
The company currently has active open charges totaling ₹1.90 Cr.
Shiva Makam and Mahesh Ganji serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100TG2021PTC151978
- Company No.
151978
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jun 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Credas Labs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shiva Makam  | Director | 29-Nov-2022 | Current |
| Mahesh Ganji | Director | 29-Nov-2022 | Current |
Financial Performance of Credas Labs.
Credas Labs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 36.35% increase. The company also saw a substantial improvement in profitability, with a 147.16% increase in profit. The company's net worth Soared by an impressive increase of 2859.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Credas Labs?
Unlock access to Credas Labs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Makved Chemical Private LimitedShiva Makam and Mahesh Ganji are mutual person
Charges (Loans)
₹19.00 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 1.90 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jun 2024 | Canara Bank | ₹1.90 Cr | Open |
How Many Employees Work at Credas Labs?
Credas Labs has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Credas Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Credas Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
